| Bioactivity | Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1[1]. | ||||||||||||
| Invitro | Fraxinellone (0-100 μM；12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Fraxinellone | ||||||||||||
| CAS | 28808-62-0 | ||||||||||||
| Formula | C14H16O3 | ||||||||||||
| Molar Mass | 232.28 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Fraxinellone
CAS: 28808-62-0 F: C14H16O3 W: 232.28
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibit
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.